IV infusion

IV infusion

30 minutes

30 minutes

3-week cycle

Days 1 and 8 of each 21-day cycle

  • Recommended dose of FYARRO is 100 mg/m2 administered as an IV infusion over 30 minutes on days 1 and 8 of each 21-day cycle
    • — 

      Recommended dose until disease progression or unacceptable toxicity

  • No known dose adjustment necessary based on age, gender, race, or impaired renal function
  • FYARRO can cause serious adverse reactions. Withhold, resume at reduced dose, or permanently discontinue FYARRO based on severity (see Dosage and Administration within full Prescribing Information)
Dose Reductions

Reduce the dosage of FYARRO to 56 mg/m2 when used concomitantly with a moderate or weak cytochrome P-450 3A4 (CYP3A4) inhibitor. Avoid concomitant use with drugs that are strong CYP3A4 and/or P-glycoprotein (P-gp) inhibitors and inducers and with grapefruit and grapefruit juice.

Hepatic Impairment

Use in patients with severe hepatic impairment is not recommended. Dose reductions to 75 mg/m2 and 56 mg/m2 are recommended in patients with mild and moderate hepatic impairment, respectively.